Silence Therapeutics (SLN) Operating Leases (2023 - 2026)
Silence Therapeutics recorded quarterly Operating Leases of $43000.0 in Q1 2026, down 39.44% quarter-over-quarter from $71000.0 in Q4 2025.
Silence Therapeutics' Operating Leases history runs 3 years deep, the most recent figure standing at $43000.0 for Q1 2026.
- In Q1 2026, Operating Leases changed N/A year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $43000.0 (changed N/A YoY), while the FY2025 annual figure was $71000.0, changed N/A from the prior year.
- Operating Leases came in at $43000.0 for Q1 2026 at Silence Therapeutics, down from $71000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $264981.1 in Q1 2023 to a low of $43000.0 in Q1 2026.
- A 3-year average of $118281.6 and a median of $97000.0 in 2025 frame the typical range for Operating Leases.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Dec 31, 2023 | 115,427.13 |
| Mar 31, 2023 | 264,981.08 |